Comparing of Denali Therapeutics Inc. (DNLI) and Turning Point Therapeutics Inc. (NASDAQ:TPTX)

Denali Therapeutics Inc. (NASDAQ:DNLI) and Turning Point Therapeutics Inc. (NASDAQ:TPTX) are two firms in the Biotechnology that compete against each other. Below is a comparison of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Denali Therapeutics Inc. 16 0.00 49.72M -0.56 0.00
Turning Point Therapeutics Inc. 45 0.00 21.28M -9.88 0.00

In table 1 we can see Denali Therapeutics Inc. and Turning Point Therapeutics Inc.’s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us Denali Therapeutics Inc. and Turning Point Therapeutics Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Denali Therapeutics Inc. 311,919,698.87% -10.2% -8.4%
Turning Point Therapeutics Inc. 47,267,880.94% 0% 0%

Liquidity

Denali Therapeutics Inc.’s Current Ratio and Quick Ratio are 11.6 and 11.6 respectively. The Current Ratio and Quick Ratio of its competitor Turning Point Therapeutics Inc. are 11.2 and 11.2 respectively. Denali Therapeutics Inc. therefore has a better chance of paying off short and long-term obligations compared to Turning Point Therapeutics Inc.

Analyst Recommendations

Denali Therapeutics Inc. and Turning Point Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Denali Therapeutics Inc. 0 1 3 2.75
Turning Point Therapeutics Inc. 0 0 5 3.00

Denali Therapeutics Inc. has a consensus target price of $28, and a 54.19% upside potential. Competitively the average target price of Turning Point Therapeutics Inc. is $63.2, which is potential 19.02% upside. Based on the analysts belief we can conclude, Denali Therapeutics Inc. is looking more favorable than Turning Point Therapeutics Inc.

Insider & Institutional Ownership

Denali Therapeutics Inc. and Turning Point Therapeutics Inc. has shares owned by institutional investors as follows: 84.5% and 37.9%. Insiders owned 0.1% of Denali Therapeutics Inc. shares. Competitively, Turning Point Therapeutics Inc. has 8% of it’s share owned by insiders.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Denali Therapeutics Inc. 3.14% 2.59% -10.33% 12.96% 71.35% 3.34%
Turning Point Therapeutics Inc. -0.38% -7.07% 19% 0% 0% 37.85%

For the past year Denali Therapeutics Inc. has weaker performance than Turning Point Therapeutics Inc.

Summary

Denali Therapeutics Inc. beats on 6 of the 11 factors Turning Point Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company to develop and commercialize therapeutic product candidates for neurodegenerative diseases; and a strategic partnership with Lonza Pharma & Biotech to develop and produce biologic medicines for neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.